寡核苷酸合成市场规模、份额及成长分析（按产品、类型、应用、最终用户和地区）－2025-2032 年产业预测

寡核苷酸合成市场规模预计在 2023 年达到 78 亿美元，并将从 2024 年的 92.1 亿美元成长到 2032 年的 348.6 亿美元，预测期内（2025-2032 年）的复合年增长率为 18.1%。

由于慢性病盛行率的上升和医学研发投入的大量增加，全球对寡核苷酸合成的需求预计将大幅增加。向精准和个人化医疗的转变，以及基因治疗的日益接受，预计将为寡核苷酸合成提供者开闢新的途径。此外，合成技术的进步和基于核酸的疗法的更广泛应用可能会进一步扩大市场机会。在强劲的医疗保健研究支出的支持下，北美预计将引领市场。然而，高合成成本、复杂的监管环境、基因治疗的伦理考量以及有限的製造能力等挑战可能会阻碍在这一发展环境中的成长。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管分析

寡核苷酸合成市场规模（依产品和复合年增长率） (2025-2032)

• 市场概览
• 寡核苷酸
  • DNA
  • 基于列
  • 基于数组
  • RNA
  • 科技
  • 基于列
  • 基于数组
  • 类型
  • 短 RNA 寡核苷酸（<65 nt）
  • 长 RNA 寡核苷酸（>65 nt）
  • CRISPR（sgRNA）
• 试剂
• 装置

寡核苷酸合成市场规模（按类型和复合年增长率） (2025-2032)

• 市场概览
• 自订寡核苷酸
• 预先设计的寡核苷酸

寡核苷酸合成市场规模（依应用）及复合年增长率（2025-2032）

• 市场概览
• 治疗应用
• 诊断
• 调查
• 其他的

寡核苷酸合成市场规模（依最终用户和复合年增长率） (2025-2032)

• 市场概览
• 学术研究所
• 製药和生物技术公司
• 诊断实验室
• 其他的

寡核苷酸合成市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Thermo Fisher Scientific（USA）
• Merck KGaA（Germany）
• Agilent Technologies（USA）
• LGC Biosearch Technologies（UK）
• Integrated DNA Technologies（IDT）（USA）
• Eurofins Genomics（Luxembourg）
• GenScript Biotech Corporation（USA）
• Twist Bioscience（USA）
• Bio-Synthesis Inc.（USA）
• ATUM（USA）
• DNA Script（France）
• SGI-DNA（USA）
• Eurogentec（Kaneka）（Belgium）
• Creative Biogene（USA）
• GeneCust Europe（Luxembourg）
• Synbio Technologies（USA）
• Epoch Life Science, Inc.（USA）
• Bioneer Corporation（South Korea）
• Genewiz（Azenta Life Sciences）（USA）

结论和建议

Oligonucleotide Synthesis Market size was valued at USD 7.8 billion in 2023 and is poised to grow from USD 9.21 billion in 2024 to USD 34.86 billion by 2032, growing at a CAGR of 18.1% during the forecast period (2025-2032).

The global demand for oligonucleotide synthesis is poised for significant growth, driven by the rising incidence of chronic diseases and substantial investments in medical research and development. The increasing shift towards precision and personalized medicine, alongside the growing acceptance of gene therapies, is expected to open new avenues for oligonucleotide synthesis providers. Additionally, advancements in synthesis technologies and the broader application of nucleic acid-based therapeutics will further enhance market opportunities. North America, supported by robust healthcare research spending, is projected to lead the market. However, challenges such as high synthesis costs, complex regulatory environments, ethical considerations surrounding gene therapies, and limited manufacturing capabilities could impede growth in this evolving landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Oligonucleotide Synthesis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Oligonucleotide Synthesis Market Segments Analysis

Global Oligonucleotide Synthesis Market is segmented by Product, Type, Application, End User and region. Based on Product, the market is segmented into Oligonucleotide, Reagents and Equipment. Based on Type, the market is segmented into Custom Oligos and Predesigned Oligos. Based on Application, the market is segmented into Therapeutic Applications, Diagnostics, Research and Others. Based on End User, the market is segmented into Academic Research Institutes, Pharmaceutical and Biotechnology Companies,, Diagnostic Laboratories and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Oligonucleotide Synthesis Market

The oligonucleotide synthesis market is primarily driven by the pivotal role oligonucleotides play in essential diagnostic techniques, including PCR, qPCR, and next-generation sequencing (NGS). As the demand for early diagnostic solutions rises swiftly, this trend is expected to pave the way for significant growth opportunities within the oligonucleotide synthesis sector in the future. The increasing reliance on these nucleic acid sequences in various biomedical applications highlights their importance, thereby reinforcing the market's potential to expand in response to innovations and advancements in diagnostic methodologies and technologies.

Restraints in the Oligonucleotide Synthesis Market

The oligonucleotide synthesis market faces significant constraints due to high costs associated with the production of high-purity or complex oligonucleotides, particularly those needed for therapeutic purposes. The expenses linked to purification processes and quality control measures exacerbate this financial challenge, making it difficult for smaller biotech companies to access these essential resources. As a result, the high operational costs restrict the ability of these firms to engage in oligonucleotide synthesis, ultimately hindering innovation and development within the industry. This economic barrier can limit competition and slow down advancements in therapeutic solutions reliant on oligonucleotides.

Market Trends of the Oligonucleotide Synthesis Market

The oligonucleotide synthesis market is witnessing a dynamic trend towards the integration of artificial intelligence (AI) and automation, significantly enhancing the efficiency, accuracy, and scalability of synthesis processes. These advancements are not only streamlining operational workflows but are also reducing costs, making oligonucleotide synthesis more accessible to researchers and biotech companies. Automated synthesizers combined with AI-driven design tools are increasingly popular, enabling rapid customization and development of oligonucleotides for various applications, including gene therapy and diagnostics. This technological shift is poised to transform the landscape of the oligonucleotide synthesis market, driving growth and innovation well into the future.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis

Global Oligonucleotide Synthesis Market Size by Product & CAGR (2025-2032)

• Market Overview
• Oligonucleotide
  • DNA
  • Column-based
  • Array-based
  • RNA
  • Technology
  • Column-based
  • Array-based
  • Type
  • Short RNA Oligos (<65 nt)
  • Long RNA Oligos (>65 nt)
  • CRISPR (sgRNA)
• Reagents
• Equipment

Global Oligonucleotide Synthesis Market Size by Type & CAGR (2025-2032)

• Market Overview
• Custom Oligos
• Predesigned Oligos

Global Oligonucleotide Synthesis Market Size by Application & CAGR (2025-2032)

• Market Overview
• Therapeutic Applications
• Diagnostics
• Research
• Others

Global Oligonucleotide Synthesis Market Size by End User & CAGR (2025-2032)

• Market Overview
• Academic Research Institutes
• Pharmaceutical and Biotechnology Companies,
• Diagnostic Laboratories
• Others

Global Oligonucleotide Synthesis Market Size & CAGR (2025-2032)

• North America (Product, Type, Application, End User)
  • US
  • Canada
• Europe (Product, Type, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Type, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Type, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Type, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Thermo Fisher Scientific (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LGC Biosearch Technologies (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Integrated DNA Technologies (IDT) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Genomics (Luxembourg)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GenScript Biotech Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Twist Bioscience (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Synthesis Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ATUM (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DNA Script (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SGI-DNA (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurogentec (Kaneka) (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Creative Biogene (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GeneCust Europe (Luxembourg)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Synbio Technologies (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Epoch Life Science, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bioneer Corporation (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genewiz (Azenta Life Sciences) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations